LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Akcijų sąrašas・Fate Therapeutics Inc

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.33 -3.62

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.25

Max

1.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.8M -32M
Pardavimai	-372K 1.4M
Pelnas, tenkantis vienai akcijai	-0.27
Pelno marža	-1,852.384
Darbuotojai	181
EBITDA	-13M -42M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+164.14% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.2M 173M
Ankstesnė atidarymo kaina	4.95
Ankstesnė uždarymo kaina	1.33

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

0.9101 / 1.14 Palaikymas ir pasipriešinimas

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Diana Shipping Increases Offer to Acquire Genco -- Update

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026-03-06 22:26; UTC

Svarbiausios naujienos

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026-03-06 22:07; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026-03-06 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-06 21:37; UTC

Uždarbis

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026-03-06 21:25; UTC

Svarbiausios naujienos

How The Iran War Impacts Ukraine. -- Barrons.com

2026-03-06 21:17; UTC

Uždarbis

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026-03-06 20:50; UTC

Uždarbis

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026-03-06 20:46; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-06 20:31; UTC

Svarbiausios naujienos

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026-03-06 20:18; UTC

Rinkos pokalbiai

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026-03-06 20:12; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026-03-06 19:10; UTC

Rinkos pokalbiai

Svarbiausios naujienos

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026-03-06 18:54; UTC

Rinkos pokalbiai

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026-03-06 18:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026-03-06 18:08; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 17:49; UTC

Rinkos pokalbiai

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

2026-03-06 17:46; UTC

Svarbiausios naujienos

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

2026-03-06 17:40; UTC

Rinkos pokalbiai

Uždarbis

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

2026-03-06 17:40; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 17:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

2026-03-06 17:28; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-06 17:20; UTC

Įsigijimai, susijungimai, perėmimai

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

164.14% į viršų

12 mėnesių prognozė

Vidutinis 3.83 USD 164.14%

Aukščiausias 7 USD

Žemiausias 2 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Fate Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.9101 / 1.14Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.